Related Experiment Video

Updated: May 16, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Monocyte-suppressing effects of simvastatin in patients with isolated hypertriglyceridemia

Robert Krysiak1, Boguslaw Okopien

  • 1Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medykow 18, Katowice, Poland. r.krysiak@interia.pl

European Journal of Internal Medicine
|November 20, 2012
PubMed

Insights

Simvastatin treatment significantly reduced inflammatory markers and monocyte cytokine release in patients with isolated hypertriglyceridemia and peripheral artery stenosis.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Isolated hypertriglyceridemia is linked to systemic inflammation.
  • The impact of statins on monocyte cytokine release in this population was previously unstudied.

Purpose of the Study:

  • To investigate the effect of simvastatin on monocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.
  • To assess simvastatin's anti-inflammatory properties in this specific patient group.

Main Methods:

  • A randomized, placebo-controlled trial involving 43 patients with isolated hypertriglyceridemia and peripheral artery stenosis.
  • Participants received either simvastatin (40 mg twice daily) or placebo for 12 weeks.
  • Evaluated plasma lipids, glucose homeostasis, C-reactive protein, and monocyte cytokine release.

Main Results:

  • Simvastatin significantly reduced monocyte release of tumor necrosis factor-α, interleukin-6, interleukin-1β, and monocyte chemoattractant protein-1.
  • Plasma C-reactive protein levels were also decreased by simvastatin treatment.
  • Placebo did not show these anti-inflammatory effects.

Conclusions:

  • Simvastatin demonstrates systemic anti-inflammatory properties in patients with isolated hypertriglyceridemia.
  • The drug effectively reduces monocyte secretory function, contributing to decreased systemic inflammation.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...